Skip to main content

AlphaLISA Human PD-L1 Detection Kit, 5,000 Assay Points

The AlphaLISA® Human PD-L1 Detection Kit is designed for detection and quantitation of human Programmed death ligand 1 (PD-L1; CD274/B7-H1) in cell culture media or serum using a homogeneous (no-wash steps, no separation steps) assay.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Part Number: AL355HV
Unit Size:
Part Number: AL355C
Unit Size:
Part Number: AL355F
Unit Size:
  • Formats:

    • Our HV (100 assay point) kits allow you to run 100 wells in 96-well format, using a 100 µL reaction volume (10 µL of sample).
    • Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).
    • Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).

    Features:

    • No-wash steps, no separation steps
    • ELISA alternative technology
    • Sensitive detection
    • Broad sample compatibility
    • Small sample volume
    • Results in less than 3 hours
    • Half the time of an ELISA assay

    Programmed death ligand 1 (PD-L1), also known as cluster of differentiation 274 (CD274) or B7 homolog1 (B7-H1) belongs to the growing B7 family of immune proteins and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. Human PD-L1 is constitutively expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. PD-L1, together with PD-L2, are two ligands for PD-1 (programmed death 1), a member of the CD28 family of immunoreceptors. By binding to PD-1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

    AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

  • Application
    Protein Analysis & Detection
    Assay Points
    5000
    Assay Target Class
    Biomarker
    Protein
    Automation Compatible
    Yes
    Brand
    AlphaLISA
    Detection Method
    Alpha
    Experimental Type
    In vitro
    Format
    Microplates
    Therapeutic Area
    Oncology

Resources

1-2 of 2 Resources
Application Note Icon Image
Application Note
Protocol Optimization for Detection and Quantification of Membrane-Bound Proteins Using AlphaLISA Te
alphalisa, cell surface, membrane protein, detection
Application Note Icon Image
Application Note
Rapid, No-wash Measurement of Immune Checkpoint Molecules and Cytokines in Co-cultures of Immune Cells and Cancer Cell Lines
cytokine, immune cells, cancer cell lines, biomarkers, checkpoint, application note